CasLoc logo
All Cases PTAB Litigations UPC Oppositions

TET Systems GMBH & Co. KG v. ISIS Pharmaceuticals Inc.

1:13-cv-01695

Overview

Case Number 1:13-cv-01695
Filing Date 2013-10-14
Status Terminated
Termination Date 2013-10-31
Court District Court, D. Delaware (ded)
Nature of Suit 830 Patent
Jurisdiction Type Federal Question
Cause of Action 35:271 Patent Infringement
Jury Demand Plaintiff

Parties

Defendant

ISIS Pharmaceuticals Inc. Operating Company

Represented By

0 Attorneys Listed
No attorneys available

Plaintiff

TET Systems GMBH & Co. KG Operating Company

Represented By

1 Attorneys Listed

Christopher Viceconte

Gibbons P.C.

Tel: +1 (302) 518-6322
Fax: +1 (302) 397-2050

300 Delaware Avenue, Suite 1050

Court & Judges

Court

District Court, D. Delaware (ded)

Global Patent Family Cross-Litigation Radar

CasLoc 360Β° Radar 14 Family Members

Multi-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions

πŸ‡ΊπŸ‡Έ
U.S. District Courts Counterparts in force
πŸ›οΈ
USPTO PTAB Trials Counterparts in force
πŸ‡ͺπŸ‡Ί
Unified Patent Court (UPC) Counterparts in force
πŸ‡©πŸ‡ͺ
European Patent Office (EPO) Counterparts in force
Worldwide Family Members (14): πŸ‡ΊπŸ‡Έ US
Parallel Proceedings Across Jurisdictions (0 found):

No active co-pending lawsuits found across other jurisdictions for this family. All related sibling filings are currently unlitigated.

Stay ahead of cross-border rulings. Subscribe for free automated docket alerts across U.S. Courts, PTAB, UPC, and EPO.

Patents Involved

2 Patents

There are 2 patents involved in this case.

Patent Asset Filing & Issue Date Expiration & Term Status External Links
US5464758
Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters
Filed: 1993-06-14
Issued: 1995-11-07
Expired (Term Ended)
Expires: 2013-06-14
US6914124
Tetracycline-regulated transcriptional activator fusion proteins
Filed: 2001-02-05
Issued: 2005-07-05
Expired (Term Ended)
Expires: 2014-03-29

Patent Enforceability & Injunction Risk Assessment

Statutory Analysis
Injunction Viability (35 U.S.C. Β§ 283) Statutorily Barred

Statutorily Barred β€” Patent expired. Under 35 U.S.C. Β§ 283, injunctive relief is barred.

Terminal Disclaimer & Cellect Risk Low Risk

Standard Statutory Term β€” No obviousness-type double patenting noted.

Damages Lookback Horizon 6-Yr Max Lookback

Under 35 U.S.C. Β§ 286, damages cannot accrue for infringement prior to 6 years before filing. All Statutory Maintenance Fees Paid (12-Year Window Cleared).

Docket Entries

(11 total)
Pleading / Complaint

COMPLAINT OR PATENT INFRINGEMENT filed with Jury Demand against ISIS Pharmaceuticals Inc. - Magistrate Consent Notice to Pltf. ( Filing fee $ 400, receipt number 311-1385862.) - filed by TET Systems GMBH & Co. KG. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, part 1 of 2, # 3 Exhibit 2, part 2 of 2, # 4 Civil Cover Sheet)(dmp, ) (Entered: 10/15/2013)

Entry #1 • 2013-10-14
1

Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (dmp, ) (Entered: 10/15/2013)

Entry #2 • 2013-10-14
1

Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 5,464,758; 6,914,124;. (dmp, ) (Entered: 10/15/2013)

Entry #3 • 2013-10-14
1

Disclosure Statement pursuant to Rule 7.1 filed by TET Systems GMBH & Co. KG. (dmp, ) (Entered: 10/15/2013)

Entry #4 • 2013-10-14
1

No Summons Issued. (dmp, )

Entry #5 • 2013-10-14
1
No Actions

Track Case Updates

Automated email notifications for new filings & decisions

Identifier: •

Free service • 1-click unsubscribe anytime • Powered by CasLoc